Meeting Brief — print or save as PDF using your browser's Print menu (⌘P / Ctrl+P).

ACS CAN Leadership Summit & Lobby Day 2026

September 15, 2026 – September 17, 2026 · Washington, DC

Brief generated June 30, 2026 · Pulse of the Hill

1organization
44bills on the agenda
12lobbyists
$2,430KLDA spend (latest year)

Who's in the room

Bills on the agenda

H.R. 3521 — Clinical Trial Modernization Act
Sponsor: Rep. Raul Ruiz [D-CA-25] · Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Cosponsors: 5 (3D / 2R)
H.R. 4184 — To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
Sponsor: Rep. Mike Kelly [R-PA-16] · Referred to the House Committee on Ways and Means.
Cosponsors: 1 (1D / 0R)
H.R. 1406 — Lung Cancer Screening and Prevention Act of 2025
Sponsor: Rep. Vern Buchanan [R-FL-16] · Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Cosponsors: 9 (6D / 3R)
H.R. 1834 — Breaking the Gridlock Act
Sponsor: Rep. James McGovern [D-MA-2] · Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 319.
H.R. 247 — Health Care Affordability Act of 2025
Sponsor: Rep. Lauren Underwood [D-IL-14] · Referred to the House Committee on Ways and Means.
S. 46
Cited in 2 LD-2 filings
S. 2761
Cited in 2 LD-2 filings
S. 2771
Cited in 2 LD-2 filings
H.R. 5145
Cited in 2 LD-2 filings
H.R. 5269
Cited in 2 LD-2 filings
H.R. 5328
Cited in 2 LD-2 filings
H.R. 6178
Cited in 2 LD-2 filings
H.R. 6501
Cited in 2 LD-2 filings
H.R. 6575
Cited in 2 LD-2 filings
H.R. 140
Cited in 1 LD-2 filing
S. 297
Cited in 1 LD-2 filing
S. 864
Cited in 1 LD-2 filing

Issue areas

Healthcare

LDA-disclosed footprint

Top issues by lobbying activity volume:

Lobbyists likely in your meeting